GlaxoSmithKline’s HIV drug Cabenuva scores FDA nod for 2-month dosing
Last January, when GlaxoSmithKline’s ViiV Healthcare won a long-awaited approval for its long-acting HIV treatment Cabenuva, it was hailed as a game-changer as it rem...
Continue Reading →
